Literature DB >> 8509403

The immunoglobulin-binding protein in vitro autophosphorylation site maps to a threonine within the ATP binding cleft but is not a detectable site of in vivo phosphorylation.

J R Gaut1, L M Hendershot.   

Abstract

In vitro incubation of immunoprecipitated immunoglobulin-binding protein (BiP) complexes with calcium and [gamma-32P]ATP resulted in the phosphorylation of BiP on a threonine residue. This autophosphorylation activity did not occur in the presence of magnesium but had the same pH optimum as reported for its magnesium-dependent ATPase activity. This suggested the possibility that both activities could occur through ATP hydrolysis at the same site. In support of this, mutation of either Thr-37 or Thr-229 to a glycine eliminated both autophosphorylation and ATPase activities, and mutation of either residue to a serine significantly reduced both activities. Glutamic acid 175 in HSC71 has been hypothesized to flank the divalent cation complexed with ATP. Mutation of the analogous glutamic acid, Glu-201, in BiP abolished ATPase activity but still supported some autophosphorylation. The in vitro phosphorylation site was mapped to Thr-229 by mutational analysis. This threonine has been hypothesized to interact with the gamma-phosphate of ATP through a polarized water molecule and would be in a position to act as a phosphate acceptor in the ATP hydrolysis reaction. These data imply that both ATPase and autophosphorylation result from ATP hydrolysis at the same site and that the cation associated with BiP determines which activity is observed. Comparison of partial protease digestion or cyanogen bromide cleavage products of in vitro and in vivo phosphorylated BiP demonstrated that Thr-229 is not a detectable site of phosphorylation in cells. Therefore, whatever functional role phosphorylation may have in vivo, it cannot be attributed to autophosphorylation of Thr-229.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8509403

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  8 in total

1.  ATPase-defective derivatives of Escherichia coli DnaK that behave differently with respect to ATP-induced conformational change and peptide release.

Authors:  T K Barthel; J Zhang; G C Walker
Journal:  J Bacteriol       Date:  2001-10       Impact factor: 3.490

2.  Unfolded protein response-regulated Drosophila Fic (dFic) protein reversibly AMPylates BiP chaperone during endoplasmic reticulum homeostasis.

Authors:  Hyeilin Ham; Andrew R Woolery; Charles Tracy; Drew Stenesen; Helmut Krämer; Kim Orth
Journal:  J Biol Chem       Date:  2014-11-13       Impact factor: 5.157

3.  Induction of stress proteins in anoxic and hyperthermicSpodoptera frugiperda cells.

Authors:  W Hugler; K C O'Connor; S J Landry; J E Bivins
Journal:  Cytotechnology       Date:  1995-01       Impact factor: 2.058

4.  Histidine 89 is an essential residue for Hsp70 in the phosphate transfer reaction.

Authors:  Yuanming Lu; Qian Hu; Cuixia Yang; Feng Gao
Journal:  Cell Stress Chaperones       Date:  2006       Impact factor: 3.667

Review 5.  BiP (GRP78), an essential hsp70 resident protein in the endoplasmic reticulum.

Authors:  I G Haas
Journal:  Experientia       Date:  1994-11-30

6.  Alpha-crystallin/small heat shock protein has autokinase activity.

Authors:  M Kantorow; J Piatigorsky
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-12       Impact factor: 11.205

7.  Heat shock of Escherichia coli increases binding of dnaK (the hsp70 homolog) to polypeptides by promoting its phosphorylation.

Authors:  M Y Sherman; A L Goldberg
Journal:  Proc Natl Acad Sci U S A       Date:  1993-09-15       Impact factor: 11.205

8.  Crystal structures of the ATPase domains of four human Hsp70 isoforms: HSPA1L/Hsp70-hom, HSPA2/Hsp70-2, HSPA6/Hsp70B', and HSPA5/BiP/GRP78.

Authors:  Magdalena Wisniewska; Tobias Karlberg; Lari Lehtiö; Ida Johansson; Tetyana Kotenyova; Martin Moche; Herwig Schüler
Journal:  PLoS One       Date:  2010-01-11       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.